What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Disease
- Gene
Her primary areas of investigation include Inflammatory bowel disease, Internal medicine, Ulcerative colitis, Immunology and Gastroenterology.
To a larger extent, Severine Vermeire studies Disease with the aim of understanding Inflammatory bowel disease.
Her research investigates the connection between Internal medicine and topics such as Surgery that intersect with issues in Colectomy and Placebo.
The concepts of her Ulcerative colitis study are interwoven with issues in Faecal calprotectin, Panca, Adverse effect and Colitis.
Her Immunology research includes elements of Single-nucleotide polymorphism and Genotype.
Her Gastroenterology research is multidisciplinary, incorporating elements of Certolizumab pegol, Crohn's Disease Activity Index, Pharmacotherapy, Calprotectin and Severity of illness.
Her most cited work include:
- Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease (3292 citations)
- Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology (2329 citations)
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease (2271 citations)
What are the main themes of her work throughout her whole career to date?
Her scientific interests lie mostly in Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease.
Her work on Infliximab, Vedolizumab and Adalimumab as part of general Internal medicine research is frequently linked to In patient, thereby connecting diverse disciplines of science.
Her research in Gastroenterology intersects with topics in Pharmacokinetics, Mucosal healing, Maintenance therapy, Placebo and C-reactive protein.
Her studies in Crohn's disease integrate themes in fields like Endoscopy, Cohort and Ustekinumab.
Her Ulcerative colitis research is multidisciplinary, incorporating perspectives in Adverse effect, Tofacitinib, Colitis and Clinical trial.
Her work focuses on many connections between Inflammatory bowel disease and other disciplines, such as Immunology, that overlap with her field of interest in Single-nucleotide polymorphism.
She most often published in these fields:
- Internal medicine (53.72%)
- Gastroenterology (37.70%)
- Crohn's disease (37.03%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (53.72%)
- Ulcerative colitis (34.18%)
- Gastroenterology (37.70%)
In recent papers she was focusing on the following fields of study:
Severine Vermeire spends much of her time researching Internal medicine, Ulcerative colitis, Gastroenterology, Inflammatory bowel disease and Crohn's disease.
Her study in the field of Vedolizumab, Infliximab, Adverse effect and Endoscopy also crosses realms of In patient.
The study incorporates disciplines such as Tofacitinib, Colitis, Clinical trial, Placebo and Surrogate endpoint in addition to Ulcerative colitis.
Her Gastroenterology research includes themes of Pharmacokinetics, Therapeutic drug monitoring, Faecal calprotectin, Calprotectin and C-reactive protein.
Inflammatory bowel disease is the subject of her research, which falls under Disease.
Her biological study spans a wide range of topics, including Surgery, Dosing and Ustekinumab.
Between 2019 and 2021, her most popular works were:
- Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (118 citations)
- JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. (78 citations)
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (46 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
